S. Keidel

发表

Basic science232. Certolizumab pegol prevents pro-inflammatory alterations in endothelial cell function

H. L. Wright, R. Moots, T. Spector, 2012 .

Novel methodology to discern predictors of remission and patterns of disease activity over time using rheumatoid arthritis clinical trials data

Ehrenstein, I. Bruce, Jane Worthington, 2018, RMD Open.

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.

D. Schadendorf, P. Ascierto, E. Lipson, 2022, The New England journal of medicine.

Inhibiting HLA-B27 homodimer-driven immune cell inflammation in spondylarthritis.

P. Bowness, K. Maenaka, K. Kuroki, 2012, Arthritis and rheumatism.

RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients

Francisco Bonachela Capdevila, I. Bruce, Jane Worthington, 2022, Scientific Data.

ERAP1 and ankylosing spondylitis.

Paul Wordsworth, Jennifer J. Pointon, Liye Chen, 2013, Current opinion in immunology.

Sweet’s syndrome after adalimumab therapy for refractory relapsing polychondritis

S. Edmonds, S. Keidel, A. McColl, 2011, BMJ Case Reports.

The RA-MAP Consortium: a working model for academia–industry collaboration

Denny Verbeeck, John D. Isaacs, Michael R. Barnes, 2018, Nature Reviews Rheumatology.

Rheumatoid Disease and Other Inflammatory Arthropathies

Paul Wordsworth, C. Swales, S. Keidel, 2013 .

Corrigendum: The RA-MAP Consortium: a working model for academia–industry collaboration

D. Symmons, M. Barnes, A. Rowe, 2018, Nature Reviews Rheumatology.

Ankylosing spondylitis is associated with the anthrax toxin receptor 2 gene (ANTXR2)

M. Brown, D. Evans, Jennifer J. Pointon, 2014, Annals of the rheumatic diseases.

The impact of rheumatologist-performed ultrasound on diagnosis and management of inflammatory arthritis in routine clinical practice

S. Kelly, P. Reynolds, S. Gadola, 2017, BMC Musculoskeletal Disorders.

Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047)

D. Schadendorf, P. Ascierto, E. Lipson, 2022, Journal of Clinical Oncology.

Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial.

D. Schadendorf, E. Lipson, H. Tawbi, 2023, European journal of cancer.

Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma

D. Schadendorf, P. Ascierto, E. Lipson, 2023, NEJM Evidence.

Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).

D. Schadendorf, P. Ascierto, E. Lipson, 2023, Journal of Clinical Oncology.

Oral Abstracts 7: RA ClinicalO37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach

H. L. Wright, R. Moots, T. Spector, 2013 .

RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients

Francisco Bonachela Capdevila, J. Sergeant, A. Cuza, 2022, Scientific Data.